Health and safety company PerkinElmer Inc. said it will acquire Caliper Life Sciences Inc., a Hopkinton, Mass.-based maker of imaging and detection products for life sciences research, diagnostics and environmental markets, for $600 million in cash, or 50 cents per share. The acquisition will broaden PerkinElmer's offerings for molecular, cellular, animal and tissue imaging to enable translational medicine research, the company said. It will also add a microfluidics platform for genomics and proteomics applications for improved detection and screening through low sample use and efficiency. Caliper Life Sciences CEO Kevin Hrusovsky is expected to join PerkinElmer's senior management when the deal closes. The purchase price represents a premium of 42 percent for Caliper Life Sciences shareholders, relative to the closing price of $7.39 on Sept. 7. The acquisition is unanimously supported by both boards of directors. It is expected to be dilutive to PerkinElmer's 2012 GAAP earnings per share by approximately 5 cents and accretive to PerkinElmer's 2012 First Call consensus adjusted earnings per share by approximately 8 cents. The transaction is subject to customary closing conditions, including approval of Caliper Life Sciences stockholders, and is expected to close in the fourth quarter of 2011. For more information, visit: www.perkinelmer.com